TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01349530

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluating of usual care
Description: RESEARCH IN CURRENT CARE

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of CREATIF
Description: RESEARCH IN CURRENT CARE
Study: NCT01671137

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Rhamnosus Strain GG
Description: Lactobacillus Rhamnosus Strain GG

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactobacillus Rhamnosus Strain GG
Description: Lactobacillus Rhamnosus Strain GG
Study: NCT02821416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
Study: NCT00504543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEB071
Description: oral, twice daily
Study: NCT01370655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Study: NCT00504543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AEB071
Description: oral, twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certican
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Certican
Description: twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neoral
Description: twice daily
Study: NCT01449864

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton therapy
Description: The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
Study: NCT02883621

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cap assisted upper endoscopy
Description: A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard upper endoscopy
Description: standard examination without using a cap
Study: NCT02966717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
Study: NCT02634632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choosing to write advance directives
Study: NCT00151086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estramustine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Study: NCT02082769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Study: NCT02187861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified under arm description.
Study: NCT01370655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to MK-7145

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to HCTZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to HCTZ

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to HCTZ
Study: NCT00590655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: weight loss programme with maintenance programme
Description: After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight loss programme
Study: NCT00773331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin beta
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms every 4 weeks
Study: NCT02187861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Bendamustine will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as per the schedule specified under arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as per the schedule specified under arm description.
Study: NCT02756819

Intervention type: DRUG
Intervention: Azilsartan Medoxomil
Description: Azilsartan medoxomil tablets
Study: NCT00405340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
Study: NCT04084587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Retimax Vision Trainer
Description: The Retimax Vision Trainer is an innovative method that aims to increase visual function in patients with eye diseases of various origins and nature, allowing the patient to exploit and optimize their residual visual potential. It is aimed at patients with visual impairments of different origins and severity, such as campimetric deficits, low vision of central origin, degenerative retinal diseases, amblyopia. (1,2) It consists of a device for recording bioelectrical responses evoked during the perception of structured visual stimuli and the control of the same by the patient through a sound biofeedback mechanism. This results in an increase in visual capacity, exploiting neuronal plasticity through the activation of alternative neuronal circuits.
Study: NCT04285216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling
Description: Hot pack 10 mints,stretching,Neck isometrics, dry needling(DN) and Strain counterstrain(SCS)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strain counter strain
Description: Hot pack 10 mints, stretchings,Neck isometrics, Strain counterstrain(SCS)
Study: NCT02700425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Pacemaker
Description: Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CRT Pacemaker
Description: Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
Study: NCT01301079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients in group N (placebo) was administrated saline during surgery.
Study: NCT02477371

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fractional flow reserve-guided CABG
Description: Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values \> 0,8 are deferred.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided CABG
Description: Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
Study: NCT02155088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BYL719
Description: Dose escalation beginning at 250 mg/day
Study: NCT02668276

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard NCCN counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard NCCN counseling and Oncotype DX results
Study: NCT00200291

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: hypocaloric, low-fat diet
Description: hypocaloric, low-fat diet

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: hypocaloric, low-fat diet
Description: hypocaloric, low-fat diet
Study: NCT03416660

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Carbon Dioxide laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Carbon Dioxide laser

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Carbon Dioxide laser
Study: NCT03408587

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: Oncolytic virus

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Fully human IgG1 monoclonal antibody that binds to the CTLA-4 receptor expressed on activated T cells.
Study: NCT03273842

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06881894
Description: pre-filled syringe 6 mg

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: US-approved Neulasta
Description: pre-filled syringe 6 mg
Study: NCT01954225

Intervention type: OTHER
Group type: OTHER
Intervention: Udumbara Sutra
Description: The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
Study: NCT02205775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: 80 + 40 mg pre PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 40 + 40 mg before PCI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 5 mg twice before PCI (+ 10 mg ezetimibe)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: 10 mg twice before PCI (+ 5 mg rosuvastatin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: twice before PCI
Study: NCT03884322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prepod
Description: the prepod is either a 4 way stretch polyester blend fleece with 8 to 10% lycra, or a 95%cotton5% lycra blend knit. It comes in 4 different sizes to assure a pod that has a conforming but not restricting fit so that the infant is free to stretch in any direction at any time but is loosely held in a position of physiological flexion (the fetal position) when not stretching.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Joint compression exercises
Description: Each premature infant enrolled as a control subject received approximately 10 minutes of joint compression exercises provided by a NICU trained physical or occupational therapist 5x a week. The exercises consisted of waking the infant slowly, gently if necessary just before feeding with a simple range of motion stretching program then stabilizing an extremity and applying force distally to proximally for 6 repetitions with a brief pause between each compression.
Study: NCT03080168

Intervention type: DEVICE
Intervention: Actigraph
Description: This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
Study: NCT03032718

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Description: Whole-body vibration exercise
Study: NCT02979249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Iron
Description: for one year
Study: NCT01835405

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LiquiBand Flex

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabond Advanced

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sutures (Prolene)
Study: NCT03415633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Respiratory Polygraphy (APNIA)
Description: Randomizing to start with home respiratory polygraphy (APNIA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Polysomnography (PSG)
Description: Randomizing to start with Standard Polysomnography (PSG)
Study: NCT02155088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose escalation beginning at 800 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (nab)-paclitaxel
Description: 125 mg/m\^2 dose
Study: NCT03415633

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home Respiratory Polygraphy (APNIA)
Description: Randomizing for therapeutic decision taken with home respiratory polygraphy (APNIA)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Polysomnography (PSG)
Description: Randomizing for therapeutic decision taken with Standard Polysomnography (PSG)
Study: NCT00364377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily for duration of the study
Study: NCT03377361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT00313586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC
Study: NCT03377361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT00313586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02256735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Ritobegron Cl (KUC 7483 CL) tablets low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Study: NCT00479115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMD3100
Description: 240 mcg/kg subcutaneously, minimum of two days; maximum of eight days

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmCell CliniMACs
Description: CD34+ cell selection from peripheral collection
Study: NCT02496039

Intervention type: DRUG
Group type: OTHER
Intervention: NUEDEXTA®
Description: NUEDEXTA® only
Study: NCT01010802

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin human recombinant (EPOrh)
Description: Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
Study: NCT01728441

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paclitaxel Eluting Stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Eluting Balloon
Study: NCT03297021

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ondansetron 4 MG
Description: dose as per arm selection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 MG
Description: dose as per arm selection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg
Description: dose as per arm selection
Study: NCT03377361

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Specified dose on specified days
Study: NCT02345109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transtek DUT
Description: Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transtek DUT
Description: Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.~Measure each participants by Transtek DUT.
Study: NCT01514877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
Study: NCT03939650

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diaana
Description: Diaana, the AMHTD used, functions as follows: on the basis of an interactive questionnaire completed by the patient before the consultation, it performs an exhaustive anamnesis focused on the problem and proposes a panel of DDs with a high sensitivity. The artificial reasoning system of Diaana mimics how a specialist physician would reason to establish a DD. The information transmitted is in an easy-to-use form for the physician that includes a summary of the anamnesis centered on relevant elements from the questionnaire and a list of possible diagnoses with their emergency level, potential contributing factors, and first-line management proposals.
Study: NCT03731208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: The telerehabilitation program equipment consists of the following devices:~* a tablet with a keyboard and a fingerprint sensor~* two wearable sensors~* a wireless modem~* measuring tape
Study: NCT04605718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.
Study: NCT02345109

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference
Description: Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
Study: NCT04605718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7223280
Description: For Part 1 (SAD) and Part 2 (MAD), RO7223280 will be administered by intravenous (IV) infusion at escalating doses from 10mg to 4800mg, as per the dosing schedules described above. These are putative doses and the maximum daily dose that must not be exceeded is 5000mg. For Part 3 (Elderly), RO7223280 will be administer as one single IV dose of 300 mg.